Is Coral Labs. overvalued or undervalued?

As of 27 October 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.67, an EV to EBITDA of 4.23, and a Price to Book Value of 0.89, which indicate that the stock is trading at a discount relative to its earnings and assets.
In comparison to its peers, Coral Labs has a significantly lower PE ratio than Sun Pharma, which stands at 35.43, and Divi's Lab at 74.62, both of which are classified as expensive. Additionally, Coral Labs' EV to EBITDA ratio is more favorable compared to peers like Cipla (16.74) and Dr. Reddy's Labs (11.31), reinforcing its position as an attractive investment. Despite a challenging year-to-date return of -34.46% compared to the Sensex's 8.50%, the long-term performance over three years shows a robust return of 98.79%, suggesting potential for recovery and growth.